Bifidobacterium lactis and probiotic preparation as well as preparation method and application of fermentation product
By developing Bifidobacter lactis YQWS2301 and its fermentation products, combined with traditional Chinese medicine extracts, the adverse reaction problem of targeting carbohydrate hydrolase inhibitors in the prior art was solved, and the α-amylase and α-glucosidase were achieved Effective inhibition, good blood sugar regulation and antioxidant ability, suitable for improving the intestinal environment and regulating blood sugar.
Patent Information
- Application Number
- CN202411008459.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
AI Technical Summary
In the treatment of diabetes, targeted carbohydrate hydrolase inhibitors often cause adverse reactions, such as abdominal distension, diarrhea, gastrointestinal cramps, nausea, etc., and there are few studies on Bifidobacter lactobacillus lactis with antidiabetic effects, and related probiotics There are fewer bacterial products, making it difficult to effectively regulate intestinal flora and reduce blood sugar.
Developed a Bifidobacterium lactis YQWS2301 and its fermentation product. By inhibiting α-amylase and α-glucosidase, it regulates the intestinal flora, has antioxidant ability and inhibits various pathogens, and is used to prepare blood sugar inhibition The elevated probiotic preparations and fermentation products combine traditional Chinese medicine extracts and other auxiliary hypoglycemia strains to play a synergistic hypoglycemia-lowering effect.
The fermentation product of Bifidobacter lactis YQWS2301 has unexpected inhibitory effects on α-amylase and α-glucosidase, has good blood sugar regulation effect, can prevent or relieve blood sugar increase and complications, and has good anti-epidemic Oxidative and antibacterial activity, high safety, suitable for improving the intestinal environment and regulating blood sugar.
Smart Images

Figure CN118956656A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of probiotics, and in particular relates to a preparation method and use of a Bifidobacterium lactis probiotic preparation and a fermentation product. Background Art
[0002] Diabetes is a chronic metabolic disease characterized by persistent hyperglycemia due to decreased insulin secretion or impaired insulin activity. Long-term hyperglycemia can lead to a variety of complications, including cardiovascular disease, nephropathy, and retinopathy. According to the World Health Organization, the number of people with diabetes worldwide is growing at an unprecedented rate, with type 2 diabetes accounting for the majority. This trend is closely linked to evolving dietary habits and lifestyles.
[0003] α-Amylase and α-glucosidase degrade ingested complex polysaccharides and disaccharides into glucose, which is subsequently absorbed in the intestine. The concentration and activity of α-amylase and α-glucosidase often determine postprandial blood glucose levels. Inhibiting the activity of carbohydrate hydrolases (such as α-amylase and α-glucosidase) to delay glucose release and absorption, thereby lowering postprandial blood glucose levels, slowing carbohydrate metabolism, and preventing excessive glucose absorption are effective strategies for alleviating postprandial hyperglycemia in type 2 diabetes. Currently, drug therapy is the mainstay of diabetes treatment. Acarbose, for example, is a commercially available targeted carbohydrate hydrolase inhibitor that competitively binds to and inhibits the enzyme's activity. However, the use of these drugs often causes adverse reactions such as abdominal distension, diarrhea, gastrointestinal cramping, and nausea, which limits their clinical application.
[0004] Probiotics can improve diabetic symptoms by regulating the composition of intestinal microbiota, the release of enzymes and hormones. As an important probiotic present in the human body, Bifidobacterium lactis is of great significance in promoting human health and improving human immune function. After colonizing the human intestine, Bifidobacterium lactis can effectively antagonize intestinal pathogens and regulate intestinal flora. Bifidobacterium lactis has relatively high safety and relatively low production cost, and its industrial application and promotion have broad prospects. CN202111550440.0 and CN202011053404.9 respectively provide two types of Bifidobacterium lactis with anti-diabetic effects. However, there is still little research on Bifidobacterium lactis with anti-diabetic effects, and there are few related probiotic products. Therefore, there is an urgent need to develop and screen more beneficial Bifidobacterium lactis in this field. Summary of the Invention
[0005] In response to the above-mentioned needs in the field, the purpose of the present invention is to provide a method for preparing and using a probiotic preparation and fermentation product of Bifidobacterium lactis. The fermentation product of this bacterium has certain hypoglycemic ability, antioxidant ability, inhibitory effect on multiple pathogens, sensitivity to multiple antibiotics, and can regulate the homeostasis of intestinal flora.
[0006] The purpose of the present invention is achieved through the following technical solutions:
[0007] In the first aspect of the present invention, a kind of lactobacillus is provided, named Bifidobacterium animalis subsp.lactis YQWS2301;Its classification name is Bifidobacterium animalis subsp.lactis;The preservation date is January 23, 2024;The preservation unit is the General Microorganism Center of China Culture Collection of Microorganisms;The preservation address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing;The deposit number is CGMCC No.29751. Studies have shown that Bifidobacterium lactis YQWS2301. Molecular biological identification results show that the gene sequence of 16S rDNA of the Bifidobacterium lactis is as shown in SEQ ID NO.1.
[0008] In a second aspect, the present invention provides a probiotic preparation for inhibiting elevated blood sugar, the probiotic preparation containing at least Bifidobacterium lactis with a deposit number of CGMCC No. 29751 and / or a fermentation broth supernatant fraction of Bifidobacterium lactis with a deposit number of CGMCC No. 29751. It is well known in the art that the fermentation broth components of the strain include bacterial cells, residual fermentation medium components, strain metabolites, etc. The bacterial cells can be obtained by centrifuging the fermentation broth, and the precipitate is enriched with bacterial cells; the residual fermentation medium components, strain metabolites, etc. can be obtained by centrifuging the fermentation broth, and the fermentation broth supernatant fraction is enriched with fermentation medium components and strain metabolites. Strain metabolites generally include organic acids, amino acids, exopolysaccharides, etc. The organic acids (especially short-chain fatty acids, etc.) and exopolysaccharides produced by strain metabolism are considered to be the main active ingredients for regulating blood sugar metabolism. Obviously, since the fermentation broth of the strain contains bacterial cells and strain metabolites, the probiotic preparation can also be prepared using the fermentation broth of Bifidobacterium lactis with a deposit number of CGMCC No. 29751 without centrifugation. Obviously, after the strain is fermented, some of its metabolites and exopolysaccharides will enter the fermentation liquid, while some of the metabolites and exopolysaccharides will remain in the bacteria. Therefore, the bacteria also have the activity of the strain's metabolites and exopolysaccharides. This is well known in the art or can be known through logical reasoning.
[0009] In a preferred embodiment, the probiotic preparation contains the supernatant fraction of the fermentation broth of Bifidobacterium lactis with a deposit number of CGMCC No. 29751. The fermentation broth can be centrifuged, and the supernatant can be freeze-dried and taken orally in a solid form or directly taken orally in a liquid form.
[0010] In another preferred embodiment, the probiotic preparation contains Bifidobacterium lactis with a preservation number of CGMCC No. 29751, and the probiotic preparation is an oral lyophilized powder preparation, wherein the content of Bifidobacterium lactis with a preservation number of CGMCC No. 29751 in the oral lyophilized powder preparation is 1x10 9 CFU / g~150x 10 9 CFU / g. For example: 1x10 9 CFU / g, 10x10 9 CFU / g, 100x10 9 CFU / g, 150x10 9 CFU / g.
[0011] Due to the adverse effects of digestive tract pH and the like on probiotics, when the probiotic preparation contains Bifidobacterium lactis with a deposit number of CGMCCNo.29751, the preferred probiotic preparation is an enteric-coated capsule or microcapsule. Probiotics can be protected by enteric-coated capsules or microcapsules, reducing the killing effect of unfavorable environments such as gastric acid on probiotics, improving the colonization of probiotics in the intestine, thereby facilitating the better health regulation of probiotics after intestinal colonization. Microcapsules are commonly used in the art for embedding and protecting oral probiotics. The wall material and preparation method of the microcapsules can refer to, but are not limited to, the wall material and preparation method reported in CN202410215369.8 and CN202410338486.3.
[0012] Preferably, the probiotic preparation further contains at least one of the following components: a Chinese herbal extract that assists in lowering blood sugar, Lactobacillus plantarum that assists in lowering blood sugar, Lactobacillus brevis that assists in lowering blood sugar, Lactobacillus rhamnosus that assists in lowering blood sugar, Lactobacillus casei that assists in lowering blood sugar, Lactobacillus acidophilus that assists in lowering blood sugar, Lactobacillus fermentum that assists in lowering blood sugar, Pediococcus pentosaceus that assists in lowering blood sugar, and Leuconostoc that assists in lowering blood sugar.
[0013] A large number of traditional Chinese medicines and their extracts have been shown to have auxiliary hypoglycemic effects, including but not limited to: Pueraria root extract, Astragalus root extract, Artemisia argyi flavonoid extract, Forsythia suspensa polysaccharide extract, Gardenia jasminoides flavonoid extract, Trichosanthes kirilowii seed polysaccharide extract, Gynostemma pentaphyllum extract, Morus alba leaf extract, Platycodon grandiflorum extract, Lycium barbarum extract, Polygonatum sibiricum polysaccharide extract, and Achyranthes bidentata extract. These traditional Chinese medicine extracts can be added to the probiotic preparation to achieve a synergistic hypoglycemic effect.
[0014] Lactobacillus plantarum CFFM1031, Lactobacillus plantarum NXU0011, Lactobacillus plantarum X1, Lactobacillus plantarum CCFM36, Lactobacillus brevis CCFM648, Lactobacillus rhamnosus Y37, Lactobacillus casei CCFM419, Lactobacillus acidophilus ATTC5220, Lactobacillus fermentum GD01, Lactobacillus fermentum LF028, Pediococcus pentosaceus SBC5, Leuconostoc pseudomesenteroides XG5, etc. have been shown to regulate blood sugar levels through multiple signaling pathways or targets. The above-mentioned probiotics that assist in lowering blood sugar can be added to the probiotic preparation to jointly exert a synergistic blood sugar-lowering effect.
[0015] Studies have shown that the fermentation products of Bifidobacterium lactis, with the preservation number CGMCC No. 29751, have an unexpected inhibitory effect on α-amylase and α-glucosidase, and can exert a good blood sugar regulation effect when taken orally. Therefore, when used alone or in combination with other hypoglycemic active substances or active bacteria, it can help prevent or alleviate elevated blood sugar and the complications it brings.
[0016] In a third aspect of the present invention, a method for preparing a fermentation product for inhibiting blood sugar elevation is provided, wherein the fermentation product is a fermentation product of Bifidobacterium lactis with a deposit number of CGMCC No. 29751, and the preparation method comprises the following steps:
[0017] S1: Activate Bifidobacterium lactis with a preservation number of CGMCC No. 29751, inoculate into TPY liquid culture medium, and culture anaerobically at 37° C. for 48 h to obtain a fermentation product.
[0018] Further preferably, the preparation method further comprises the following steps:
[0019] S2: The fermentation product obtained in step S1 is centrifuged and the fermentation supernatant and the precipitate are collected.
[0020] S3: collecting the precipitate obtained in step S2, washing it with sterile saline, and resuspending it in reconstituted skim milk to obtain a bacterial suspension; collecting the fermentation broth supernatant obtained in step S2, filtering it with a microporous membrane, and obtaining a fermentation broth supernatant component;
[0021] Further preferably, the preparation method further comprises the following steps:
[0022] S4: adjusting the concentration of the bacterial suspension obtained in step S3, and freeze-drying to obtain bacterial powder; freeze-drying the fermentation liquid supernatant component obtained in step S3 to obtain a freeze-dried powder of the fermentation liquid supernatant component,
[0023] Further preferably, in step S3, the mass percentage concentration of the skim milk powder in the reconstituted skim milk is 14%; further preferably, in step S4, the concentration of the bacterial suspension before freeze-drying is adjusted to
[0024] 1.0×10 10 CFU / mL~
[0025] 2.0×10 10 CFU / mL.
[0026] The reconstituted skim milk is prepared by dissolving skim milk powder in water and sterilizing the solution at 115° C. and 0.1 MPa for 15 minutes.
[0027] Studies have shown that the bacterial suspension and its freeze-dried powder have good antibacterial activity and strong antioxidant capacity against harmful bacteria, can promote the growth of intestinal probiotics, and inhibit pathogenic bacteria, thereby helping to maintain the homeostasis of intestinal flora; among them, the Bifidobacterium lactis with a preservation number of CGMCC No. 29751 has no hemolytic activity, is sensitive to antibiotics and has good safety. The fermentation broth supernatant component has a good inhibitory effect on α-amylase and α-glucosidase, thereby having a good blood sugar regulating effect. Therefore, the fermentation product obtained in step S1 can also be further processed by the following steps: S22: freeze-drying the fermentation product obtained in step S1 to obtain a fermentation product freeze-dried powder for oral use.
[0028] A fourth aspect of the present invention provides the use of the aforementioned Bifidobacterium lactis and probiotic preparation in the preparation of a hypoglycemic agent. Preferably, the hypoglycemic agent is an oral solid or oral liquid preparation; preferably, the hypoglycemic agent exerts its hypoglycemic effect at least by inhibiting α-amylase and α-glucosidase.
[0029] The preservation information of Bifidobacterium lactis of the present invention is as follows:
[0030] Nomenclature: Bifidobacterium animalis subsp. lactis YQWS2301;
[0031] Classification name: Bifidobacterium animalis subsp. lactis;
[0032] Deposit number: CGMCC No.29751;
[0033] Depository: General Microbiology Center, China Culture Collection Administration;
[0034] Storage address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing;
[0035] Date of preservation: January 23, 2024.
[0036] The beneficial effects of the present invention include:
[0037] The Bifidobacterium lactis YQWS2301 (i.e., Bifidobacterium lactis with a deposit number of CGMCC No. 29751) provided by the present invention has a strong tolerance to simulated artificial gastrointestinal fluid, has the ability to resist intestinal pathogens and promote the growth of probiotics. A hemolytic test confirms that Bifidobacterium lactis YQWS2301 does not produce hemolysin, will not dissolve blood cells, has a certain degree of sensitivity to various antibiotics, and has good biosafety.
[0038] The Bifidobacterium lactis YQWS2301 (i.e. the Bifidobacterium lactis with the preservation number of CGMCC No. 29751) provided by the present invention has good antioxidant effect, and the scavenging rate of DPPH free radicals is 68.46%.
[0039] The fermentation broth supernatant component of Bifidobacterium lactis YQWS2301 (i.e., Bifidobacterium lactis with a preservation number of CGMCC No. 29751) provided by the present invention has an unexpected inhibitory effect on α-amylase and α-glucosidase, with an inhibition rate of up to 62.47% for α-glucosidase and 87.23% for α-amylase. Oral administration can exert a good blood sugar regulation effect. Therefore, when used alone or in combination with other hypoglycemic active substances or active bacteria, it helps to prevent or alleviate elevated blood sugar and the complications caused by it.
[0040] Therefore, the Bifidobacterium lactis YQWS2301 (i.e., Bifidobacterium lactis with a preservation number of CGMCC No. 29751) and its fermentation products provided by the present invention can be widely used in health foods or drinks for improving the intestinal environment and regulating blood sugar, and have high market application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 Figure 1 is the colony morphology and microscopic morphology of Bifidobacterium lactis YQWS2301 of Example 1;
[0042] Figure 2 The results of the antibacterial ability test of Bifidobacterium lactis YQWS2301 against pathogens in Example 4 are as follows;
[0043] Figure 3 The hemolytic test results of Bifidobacterium lactis YQWS2301 in Example 5 are as follows;
[0044] Figure 4 The antibiotic sensitivity test results of Bifidobacterium lactis YQWS2301 in Example 8 are as follows;
[0045] Figure 5This is a schematic diagram of the digestion of the microbial ecosystem model of Example 8;
[0046] Figure 6 The changes in intestinal microorganisms at the phylum level during in vitro simulated digestion in Example 8;
[0047] Figure 7 This is the change of intestinal microorganisms at the genus level during the in vitro simulated digestion of Example 8. DETAILED DESCRIPTION
[0048] In order to explain the technical content, achieved objectives and effects of the present technical solution in detail, a detailed description is given below in conjunction with specific embodiments, but this does not limit the scope of protection of the present invention.
[0049] In the following experimental examples, Bifidobacterium lactis YQWS2301 is the Bifidobacterium lactis with a deposit number of CGMCC No. 29751. Unless otherwise specified, nucleotide sequences, including primer sequences, are written from 5' to 3' end. The experimental methods used in the following experimental examples are conventional methods unless otherwise specified. Materials and reagents used in the following experimental examples, unless otherwise specified, were commercially available.
[0050] The TPY liquid culture medium used in a specific embodiment of the present invention is prepared and treated as follows: 10 g of peptone, 10 g of beef extract, 5 g of yeast extract powder, 2 g of dipotassium hydrogen phosphate, 2 g of trisodium citrate, 2 g of sodium acetate, 20 g of glucose, 1 mL of Tween-80, 0.58 g of magnesium sulfate heptahydrate, 0.25 g of manganese sulfate tetrahydrate, 1000 mL of distilled water, and 0.5 g of cysteine. Mix and adjust the pH to 6.8-7.0. (Note: 1.5%-2% agar is added to prepare the solid culture medium) and sterilize at 121°C for 20 min.
[0051] The LB liquid medium used in the specific embodiment of the present invention was prepared and treated as follows: 10 g of tryptone, 5 g of yeast extract powder, 10 g of sodium chloride, and 1000 mL of distilled water were mixed (Note: 1.5% to 2% agar was added to prepare the solid medium), and sterilized at 121°C and 0.1 MPa for 15 min.
[0052] Example 1 Isolation and Screening of Bifidobacterium lactis YQWS2301
[0053] (1) Sample collection
[0054] Fecal samples were collected from healthy infants aged 1 to 3 years who were breastfed and had not taken antibiotics for the past 3 months. The fecal samples were placed in sampling tubes filled with sterile saline. The sampling tubes were then placed in anaerobic culture bags containing anaerobic gas production bags. The culture bags were placed in a foam box filled with ice packs and quickly returned to the laboratory for processing.
[0055] (2) Strain isolation
[0056] Spread culture: Shake the collected fecal sample and dilute it with 0.9% sterile saline to prepare bacterial suspensions with different concentration gradients. Select a bacterial suspension with an appropriate gradient and spread 100 μL of the bacterial suspension on TPY solid culture medium containing mupirocin lithium salt. Place the plate in an anaerobic jar and culture anaerobically for 48 hours with vacuum.
[0057] Isolation and purification: After the coating culture is completed, single colonies with different morphologies on the plate are selected, streaked, and anaerobically cultured at 37°C for 48 hours. Pure bacteria are obtained by streaking for three generations.
[0058] Microscopic examination and preservation: Take photos of the purified third-generation single colonies to record their morphology. Pick half of the colonies for Gram staining to observe their microscopic morphology. Use a sterile inoculating loop to pick the remaining half of the colonies for microscopic examination and inoculate them into TPY liquid medium. Incubate anaerobically at 37°C for 16 hours. Take 600μL of the pure culture solution and add it to an EP tube pre-filled with 400μL of glycerol. Seal the tube with parafilm and store in a -80°C ultra-low temperature freezer.
[0059] The colony morphology and microscopic examination results of the strains are as follows Figure 1 As shown, the colonies of Bifidobacterium lactis YQWS2301 are translucent, milky white, and have a smooth, convex, rounded surface. Gram staining of Bifidobacterium lactis YQWS2301 is positive. Microscopic observation reveals Y- or V-shaped rods with blunt ends at one or both ends.
[0060] Example 2 Molecular Biological Identification of Bifidobacterium lactis YQWS2301
[0061] After activating and culturing the Bifidobacterium lactis YQWS2301 bacteria isolated and purified in Example 1, the bacterial genomic DNA was extracted using a bacterial genomic DNA extraction kit (Nanjing Novozyme Biotechnology Co., Ltd.), and the 16S rDNA sequence was amplified using the upstream primer 27F: AGTTTGATCMTGGCTCAG and the downstream primer 1492R: GGTTACCTTGTTACGACTT to obtain a PCR product. PCR reaction system: 2xRapid Taq Master Mix 25 μL, 2 μL each of the upstream and downstream primers, 3 μL of DNA template, 18 μL of ddH2O. PCR reaction conditions: 95°C for 5 min; 95°C for 30 s, 51°C for 30 s, 72°C for 1 min, 35 cycles; 72°C for 10 min.
[0062] The PCR reaction products were sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing, and the determined gene sequences were submitted to the NCBI database (www.ncbi.nlm.nih.gov) for BLAST analysis and comparison, with 16S rDNA gene sequence homology ≥99% as the identification standard.
[0063] The 16S rDNA gene sequence of the strain is shown in SEQ ID NO. 1. Identification results show that the 16S rDNA gene sequence of the strain is more than 99% homologous to that of Bifidobacterium animalis subsp. lactis. The present invention designates the strain as YQWS2301 and makes a patent deposit. The deposit information is as follows:
[0064] The strain was named as Bifidobacterium animalis subsp. lactis YQWS2301;
[0065] The taxonomic name is: Bifidobacterium animalis subsp. lactis;
[0066] The deposit date is January 23, 2024;
[0067] The depository unit is: General Microbiology Center of China Culture Collection Administration of Microorganisms;
[0068] The deposit address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing;
[0069] The deposit number is: CGMCC No.29751.
[0070] Example 3 Evaluation of the tolerance of Bifidobacterium lactis YQWS2301 to simulated artificial gastric juice and artificial intestinal juice
[0071] After activating Bifidobacterium lactis YQWS2301 and Bifidobacterium lactis Bb12 for 3 generations, 1 mL was taken and placed in 9 mL of artificial gastric juice with a pH value of 2.5 after filtration and sterilization. The samples were shaken evenly and cultured anaerobically at 37°C. The number of viable bacteria was determined. Then 1 mL of the culture fluid digested in artificial gastric juice with a pH of 2.5 for 2 hours was taken and inoculated into 9 mL of artificial intestinal juice with a pH of 8.0 after filtration and sterilization. The culture was continued at 37°C for anaerobic culture. Bifidobacterium lactis Bb12 was used as a control. There were 3 parallels in each group, and the number of viable bacteria was determined at 0 and 4 hours, respectively, to calculate the survival rate. Among them, the artificial gastric juice and artificial intestinal juice were prepared and used immediately, and refrigerated at 4°C for a short time. The survival rate calculation formula is:
[0072]
[0073] Artificial gastric juice formula: prepare 0.85% normal saline, then add 0.3% pepsin, adjust the pH value to 2.5 with dilute hydrochloric acid, fully dissolve and filter with 0.22 μm microporous filter membrane for sterilization.
[0074] Artificial intestinal fluid formula: prepare 0.85% normal saline, then add 0.1% trypsin, adjust the pH value to 8.0 with sodium hydroxide, fully dissolve and filter with a 0.22 μm microporous filter membrane for sterilization before use.
[0075] Table 1 Tolerance evaluation of gastrointestinal fluid of Bifidobacterium lactis YQWS2301
[0076] strain YQWS2301 Bb12 Viable bacterial count at 0h (CFU / mL) <![CDATA[1.64×10 9 ]]> <![CDATA[1.79×10 9 ]]> Viable bacteria count at 2h (CFU / mL) <![CDATA[8.56×10 7 ]]> <![CDATA[6.15×10 7 ]]> Viable bacteria count at 6 hours (CFU / mL) <![CDATA[2.91×10 8 ]]> <![CDATA[2.22×10 8 ]]> Gastric juice survival rate (%) 5.22 3.44 Intestinal fluid survival rate (%) 339.95 360.98 Digestive fluid survival rate (%) 17.74 12.40
[0077] As shown in Table 1, the initial viable count of Bifidobacterium lactis YQWS2301 was 1.64×10 9 At 1.5 CFU / mL, the survival rate reached 17.74% after 2 hours of treatment in gastric juice and 4 hours in intestinal juice, demonstrating superior digestive fluid survival compared to Bifidobacterium lactis Bb12, ensuring sufficient viable bacteria reach the intestines to exert their probiotic effects. Bifidobacterium lactis YQWS2301 had a 2-hour survival rate of 5.22% in gastric juice, and its viable bacterial count in intestinal juice not only did not decrease but actually increased. This demonstrates that Bifidobacterium lactis YQWS2301 has good gastrointestinal fluid tolerance and possesses considerable intestinal colonization potential.
[0078] Example 4 Evaluation of the antibacterial activity of Bifidobacterium lactis YQWS2301
[0079] Inhibitory effect of Bifidobacterium lactis on pathogenic bacteria
[0080] The experimental steps are:
[0081] (1) The activated cultured bacterial suspension of Bifidobacterium lactis YQWS2301 was inoculated into 10 mL test tubes containing TPY liquid culture medium at an inoculum volume of 3%, and the culture was carried out in an anaerobic incubator at a constant temperature of 37°C for 16 h.
[0082] (2) Escherichia coli IQCC 10126 and Staphylococcus aureus ATCC 13565 were used as indicator bacteria. The indicator bacteria liquid was inoculated into 10 mL of LB liquid culture medium at an inoculum volume of 3%, and cultured in a constant temperature incubator at 37°C for 24 h.
[0083] (3) Pour 10 mL of plain agar medium into the bottom layer of the plate, wait for it to cool and solidify, and then put it into the Oxford cup. Take 20 μL of each pathogen suspension and add it to 20 mL of LB solid medium at an appropriate temperature (about 50°C) and mix well (the number of viable indicator bacteria is 10 6CFU / mL), pour it into the prepared plain agar plate, shake it gently to mix it until it solidifies, remove the Oxford cup with tweezers, and add 160μL of the test bacterial solution (the number of viable bacteria is 10 8 CFU / mL) in triplicate, with one control using TPY liquid medium. Place the plate in an anaerobic culture bag equipped with an anaerobic gas generator. Replace the air with oxygen-free air. Carefully transfer the culture bag to an incubator and incubate horizontally at 37°C for 18 hours. After completion of the incubation, measure the diameter of the inhibition zone with a vernier caliper.
[0084] The 10 mL of LB agar medium was not used for bacterial culture. Its functions were to: make the bottom of the dish uniform, reducing experimental error; act as a buffer to prevent the bacterial solution from spreading too quickly or too slowly, resulting in uneven diffusion; and act as an adhesive to prevent bacterial solution leakage that could affect the antibacterial effect. The actual bacterial layer for the antibacterial experiment consisted of 20 mL of LB agar medium.
[0085] Table 2 Antibacterial effect of Bifidobacterium lactis YQWS2301
[0086]
[0087] See the results Figure 2 and Table 2, by Figure 2 (The plaque on the lower right side of each culture dish corresponds to the blank control) As shown in Table 2, Bifidobacterium lactis YQWS2301 has a strong inhibitory effect on common intestinal pathogens Escherichia coli and Staphylococcus aureus.
[0088] Example 5 Hemolytic activity and antibiotic tolerance experiment of Bifidobacterium lactis YQWS2301
[0089] 1. Hemolytic test
[0090] (1) Preparation of inoculum: The frozen Bifidobacterium lactis YQWS2301 strain was streaked onto TPY agar medium and cultured at 37°C for 24-48 h. After subcultured once in TPY liquid medium, Bifidobacterium lactis YQWS2301 was inoculated into fresh TPY liquid medium at a 3% inoculum volume and cultured at 37°C for 24-48 h to obtain a fresh bacterial solution as the inoculum.
[0091] (2) Preparation of blood cell culture medium: Weigh various components of TBS basal culture medium, dissolve them, and sterilize them by autoclaving at 121°C for 15 min. When the culture medium cools to 50°C, add 5% sterile defibrinated sheep blood, mix well, and pour into a plate.
[0092] (3) Streak culture: Streak the test strain onto the prepared blood cell plate and culture it in a 37°C incubator. Observe the test bacteria for hemolysis for 24 to 48 hours.
[0093] like Figure 3 As shown, after Bifidobacterium lactis YQWS2301 was streaked onto the blood cell culture medium, no hemolytic zone appeared around the colony, proving that Bifidobacterium lactis YQWS2301 did not produce hemolysin, would not dissolve blood cells, and would not cause hemolytic hazards.
[0094] 2. Antibiotic tolerance test
[0095] After the test bacteria were activated by streaking on a TPY solid plate, 3 to 5 colonies were picked and added to 5 mL of normal saline to prepare a bacterial suspension and the concentration of the bacterial suspension was adjusted to 10 8 CFU / mL, 100 μL of bacterial suspension was added to a pre-poured TPY solid plate. The bacterial suspension was evenly spread on the plate with a sterile cotton swab, and an antibiotic susceptibility plate was applied. The plate was allowed to stand for 15 minutes. After replacing the air with oxygen-free air, the plate was inverted and incubated at 37°C. After 24-48 hours, the antibiotic sensitivity diameter of the strain was measured with a vernier caliper. The results showed that the sensitivity diameters (mm) of Bifidobacterium lactis YQWS2301 to penicillin, novobiocin, clindamycin, azithromycin, cefixime, oxacillin, ciprofloxacin, erythromycin, vancomycin, ceftriaxone, cephalothin, ampicillin, rifampicin, and amoxicillin were 30, 23, 30, 35, 34, 33, 24, 14, 17, 32, 37, 30, 24, and 39, respectively. Figure 4 The figure shows the results of this test, in which the antibiotic susceptibility tablets corresponding to numbers 1-14 are amoxicillin, rifampicin, ceftriaxone, ampicillin, vancomycin, oxacillin, cefixime, ciprofloxacin, erythromycin, penicillin, azithromycin, novobiocin, and clindamycin.
[0096] Bifidobacterium lactis YQWS2301 is sensitive to 14 common antibiotics on the market, proving that Bifidobacterium lactis YQWS2301 is safe in production applications.
[0097] Example 6 Determination of the antioxidant function of Bifidobacterium lactis YQWS2301
[0098] Determination of DPPH scavenging ability of strains
[0099] (1) Preparation of PBS bacterial suspension
[0100] Inoculate the test bacterial suspension into TPY medium at a 3% concentration and incubate anaerobically at 37°C for 24 hours to obtain the culture medium. Collect the bacterial cells by centrifuging 1 mL of the culture medium at 8000 rpm for 8 minutes. Wash the cells twice with 1 mL of PBS buffer and resuspend in 2 mL of PBS for later use.
[0101] (2) Determination of the ability of strains to scavenge DPPH free radicals
[0102] Take 400 μL of the PBS suspension of the test strain, add 600 μL of a 0.4 mM freshly prepared DPPH free radical solution, mix well, and then incubate at room temperature in the dark for 30 minutes. Then measure the absorbance of the sample at a wavelength of 517 nm (A sample), and measure it three times in parallel. The control sample is 400 μL of PBS suspension and 600 μL of 80% methanol solution, and the blank sample is 400 μL of 80% methanol solution and 600 μL of DPPH free radical solution. The clearance rate is calculated according to the following formula:
[0103]
[0104] Calculation showed that the scavenging rate of DPPH free radicals of Bifidobacterium lactis YQWS2301 was 68.46%, which showed that it had strong antioxidant capacity and could effectively scavenge DPPH free radicals.
[0105] Example 7 In vitro hypoglycemic activity assay of Bifidobacterium lactis YQWS2301
[0106] 1. Preparation of Fermentation Supernatant
[0107] The test bacterial liquid was inoculated into TPY liquid culture medium at a ratio of 3% and cultured at 37°C for 24 hours, followed by centrifugation at 8000 r / min for 8 minutes. The supernatant was collected and filtered through a 0.22 μm microporous filter membrane to obtain the fermentation supernatant.
[0108] 2. α-glucosidase inhibition assay
[0109] 1.5U / mL α-glucosidase test solution: Dissolve 100U of α-glucosidase in 1mL of PBS buffer to a 100U / mL stock solution. Take 300μL of the stock solution and add 20mL of PBS to dilute to 1.5U / mL.
[0110] 20mmol / L PNPG (i.e., p-nitrophenyl-α-D-pyranoglucopyranoside): Accurately weigh 0.0788g of PNPG into a 10mL centrifuge tube, dissolve in 5mL of PBS buffer, aliquot, and store in a -20℃ refrigerator until use.
[0111] 0.2mol / L Na2CO3 terminator: Accurately weigh 2.12g Na2CO3, dissolve it in an appropriate amount of distilled water, and dilute to volume in a 100mL volumetric flask.
[0112] 35 μL of supernatant was aspirated and mixed with 165 μL of PBS buffer. 50 μL of α-glucosidase solution (1.5 U / mL) was added, mixed thoroughly, and incubated at 37°C for 5 minutes. 75 μL of PNPG (20 mmol / L) was then added and mixed thoroughly. Incubation was continued at 37°C for 15 minutes, and the reaction was terminated by adding 400 μL of Na₂CO₃. The OD value at 405 nm was measured in a microplate reader, and the inhibition rate was calculated. Each sample was tested in triplicate, with acarbose (5 μg / mL) and Bb12 used as positive controls.
[0113] The calculation formula of inhibition rate is:
[0114]
[0115] Where: A1 is the absorbance with enzyme but not sample; A2 is the absorbance without enzyme and sample; A3 is the absorbance with enzyme and sample; A4 is the absorbance with sample but not enzyme.
[0116] 3. α-amylase inhibition assay
[0117] 2.5U / mL α-amylase test solution: Take 50mg of α-amylase, dissolve it in 0.2mol / L PBS buffer to 25mL, filter, and prepare it before use.
[0118] 1% soluble starch solution: Place 0.5g of soluble starch in a 100mL beaker. Prepare 50mL of PBS buffer. Moisten the starch with a small amount of PBS buffer. Bring the remaining buffer to a boil and add it to the soluble starch. Stir the soluble starch solution in a boiling water bath for 10 minutes to allow it to fully gelatinize and dissolve. Remove the solution, cool to room temperature, and transfer it to a 50mL volumetric flask. Rinse the beaker with water, add the wash solution to the volumetric flask, and dilute to the mark. Shake well and filter. Prepare immediately before use.
[0119] 3,5-Dinitrosalicylic acid test solution (DNS): Take 6.5 g of 3,5-dinitrosalicylic acid, add 325 mL of 2 mol / L sodium hydroxide solution, 45 mL of glycerol, and then add water to 1000 mL. Dissolve thoroughly and store at room temperature until used.
[0120] Acarbose solution: Dissolve 5 mg of acarbose in 5 mL of distilled water to prepare a 1 mg / mL solution.
[0121] Mix 200 μL of fermentation supernatant with 200 μL of α-amylase working solution and incubate at 37°C for 10 minutes. Then, add 200 μL of 10 g / L soluble starch solution and continue incubating for 10 minutes. Then, add 400 μL of DNS, boil in a boiling water bath for 5 minutes, cool, add 4 mL of deionized water, mix well, and measure the OD value at 540 nm in a microplate reader. Acarbose (1 mg / mL) and Bb12 were used as positive controls. The inhibition rate was calculated as follows:
[0122]
[0123] Where: A1 is the absorbance with enzyme but not sample; A2 is the absorbance without enzyme and sample; A3 is the absorbance with enzyme and sample; A4 is the absorbance with sample but not enzyme.
[0124] Table 3 Inhibitory effect of strains on α-glucosidase and α-amylase (%)
[0125]
[0126] The results in Table 3 show that Bifidobacterium lactis YQWS2301 exhibited inhibitory effects on α-glucosidase and α-amylase, approaching those of the acarbose-positive group. Its α-glucosidase inhibition rate reached 62.47%, and its α-amylase inhibition rate reached 87.23%, significantly superior to that of Bifidobacterium lactis Bb12 (p < 0.05), demonstrating that Bifidobacterium lactis YQWS2301 possesses a potent hypoglycemic effect. Its α-glucosidase and α-amylase inhibitory activities were unexpectedly higher than those of existing Bifidobacteria lactis and approached or showed no significant difference from acarbose.
[0127] Example 8: In vitro simulation of the effect of Bifidobacterium lactis YQWS2301 on colonic pathogens
[0128] 1. Construction and operation of SHIME in vitro digestion
[0129] This study refers to the SHIME in vitro model that simulates the human intestinal microbial ecosystem and has been slightly improved ( Figure 5). The parameters of the human intestinal microbial ecosystem (SHIME) model components and the basic culture medium are shown in Tables 4 and 5, respectively. The SHIME model consists of five fermentation glass tubes as reactors, namely the stomach, small intestine, ascending colon (AC), transverse colon (TC), and descending colon (DC). Each glass fermenter is placed in a water bath at a constant temperature of 37°C, and latex tubes are used for connection and food delivery. A peristaltic pump is used to simulate the peristalsis process of the human intestine, and a magnetic stirrer is used to simulate the stirring process of various parts of the human body at 37°C. In this experiment, nitrogen gas is introduced for 20 minutes every 4 hours to simulate the anaerobic environment of the human gastrointestinal tract. Table 5 details the retention time, pH, flow rate and fermenter volume of this device. The pH of the five reactors is adjusted by a pH controller (0.1 mol / L hydrochloric acid or 0.1 mol / L sodium hydroxide) to meet the pH environment of various parts of the human body.
[0130] Before the experiment began, fecal suspensions from healthy adult volunteers were inoculated into the ascending colon (AC), transverse colon (TC), and descending colon (DC). Subjects had to have no history of gastrointestinal disease, no antibiotic use within the past 6 months, and signed informed consent before participating in the study. Freshly donated fecal samples were stored in a collection box at 4°C along with anaerobic bacteria bags. Fifty grams of feces were weighed and added to 250 mL of inoculum (sterile PBS buffer 0.1 mol / L, pH 7, with 1 g / L sodium thioglycolate as a reducing agent). The suspension was homogenized using a homogenizer and shaker. The suspension was then centrifuged at 4°C and 1000 g for 10 minutes. Finally, the supernatant was added to 50 mL of AC, 50 mL of TC, and 60 mL of DC, respectively.
[0131] The experiment is divided into four phases: stabilization period (1 week), pathogenic period (1 day), and treatment period (1 week). The stabilization period is to allow the microbial flora in the feces to better colonize and grow in the fermentation tank, accurately simulating the human intestinal microbial flora. During the pathogenic period, Staphylococcus aureus and Escherichia coli were added to the ascending colon, transverse colon, and descending colon, and the peristaltic pump was stopped. Natural colonization for 24 hours. The purpose of the treatment period is to test the effect of Bifidobacterium lactis YQWS2301 on the intestinal microbial flora. Samples were taken on the last day of each period for intestinal microbial analysis and determination of short-chain fatty acids. During the trial, 250 mL of sterile culture medium was added twice a day (Table 6). According to the recommended intake of probiotics in existing research literature and relevant international standards and regulations, in addition to the culture medium, 2.5 g / d (10 9CFU / d) freeze-dried powder of Bifidobacterium lactis YQWS2301. Following the addition of the culture medium, 50 mL of saliva, 100 mL of gastric juice, and 60 mL of intestinal fluid were added to the stomach and small intestine, respectively. The digestive fluid composition is shown in Table 6, and the electrolyte composition is shown in Table 7. After the gastric juice was prepared, the pH was adjusted to 2 with 0.1 mol / L HCl.
[0132] Table 4 Parameters of the components of the human intestinal microbial ecosystem (SHIME) model
[0133]
[0134] Table 5 Basic culture medium for microbial ecosystem model
[0135] Element Mass (g) Xylan 4 pectin 2 Arabinogalactan 1 glucose 0.4 starch 1 yeast extract 3 Peptone 3 mucin 0.75 Cysteine 0.5 distilled water 1000 (mL)
[0136] Table 6 Composition of digestive juice components
[0137]
[0138]
[0139] Table 7 Electrolyte stock solutions of various digestive solutions
[0140]
[0141] 2. Intestinal Microbial Analysis
[0142] Samples were collected from each colon and placed in cryovials, immediately placed in liquid nitrogen, and then stored in a −80°C freezer. The samples were then shipped on dry ice to Harbin Haruo Biotechnology Co., Ltd. for 16S rDNA gene amplicon sequencing. Bioinformatics analysis of the sequencing data was performed using Quantitative Insights Into Microbial Ecology (QIIME) software.
[0143] Figure 6 、 Figure 7 In Tables 8-1 and 8-2, AB, AI, AT, TB, TI, TT, DB, DI, and DT are AB: ascending colon during the stable period, AI: ascending colon during the period of pathogen inoculation, AT: ascending colon during the treatment period, TB: transverse colon during the stable period, TI: transverse colon during the period of pathogen inoculation, TT: transverse colon during the treatment period, DB: descending colon during the stable period, DI: descending colon during the period of pathogen inoculation, and DT: descending colon during the treatment period.
[0144] This experiment used high-throughput sequencing analysis to study the effects of Bifidobacterium lactis YQWS2301 on intestinal flora. Figure 6As shown, the relative abundance of intestinal microorganisms at the phylum level varied to varying degrees at different stages. The main phyla in the intestinal flora were Firmicutes, Proteobacteria, Actinobacteriota, and Bacteroidetes. During the stable period, Firmicutes was the dominant phylum in all three colons. However, after inoculation with pathogens, the levels of Proteobacteria changed significantly, with the relative abundance of Proteobacteria in the three colons increasing from 0.25%, 1.72%, and 15.80% to 37.99%, 40.04%, and 44.98%, respectively. During treatment, the relative abundance of Proteobacteria decreased significantly. Since almost all species in Proteobacteria are harmful bacteria, such as Salmonella and Escherichia coli, this demonstrates that Bifidobacterium lactis YQWS2301 has the potential to inhibit the growth of pathogens.
[0145] In order to study the essential differences in the intestinal microbial structure, the top 20 genera with the highest relative abundance were selected for comparison, e.g. Figure 7As shown. After inoculation with pathogenic bacteria, the intestinal flora of the three colons underwent significant changes. When inoculated with pathogenic bacteria, the microbial homeostasis of the intestinal flora was disrupted, among which Escherichia, Klebsiella, Salmonella, Staphylococcus, and Enterococcus increased significantly (P < 0.05). Megamonas, Lactobacillus, Bacteroides, Lachnoclostridium, Bifidobacterium, Dialister, and Phascolarctobacterium decreased significantly (P < 0.05). During treatment with Bifidobacterium lactis YQWS2301, the genera Escherichia, Klebsiella, Salmonella, and Staphylococcus decreased significantly (P<0.05), while the number of probiotics Lactobacillus, Bifidobacterium, Bacteroides, Lachnoclostridium, and Phascolarctobacterium increased significantly (P<0.05).
[0146] Judging from the experimental results, Bifidobacterium lactis YQWS2301 can significantly regulate the homeostasis of intestinal flora, promote the growth of intestinal probiotics, and inhibit certain pathogenic bacteria, so that the intestinal flora can reach a balanced state again.
[0147] 3. Determination of Short-chain Fatty Acids
[0148] A 5 mL sample was centrifuged at 13,000 g for 5 min. The supernatant was filtered through a 0.45 μm filter and analyzed by HPLC to determine the short-chain fatty acids in the sample. HPLC analysis conditions: A 20 μL aliquot was injected onto an HPX-87H column (300 × 7.8 mm, 5 μm, Bio-Rad) with 5 mM H₂SO₄ as the mobile phase, a column temperature of 50°C, a flow rate of 0.35 mL / min, and a detection wavelength of 210 nm.
[0149] Short-chain fatty acids are important metabolites of microorganisms and can indirectly reflect changes in the microbial flora. The changes in short-chain fatty acids throughout the digestive process are shown in Tables 8-1 and 8-2. A total of six short-chain fatty acids were tested in this experiment, among which lactic acid and acetic acid had relatively high levels. When the three colons were inoculated with pathogenic bacteria, the short-chain fatty acid content changed significantly (P<0.05). The content of all six short-chain fatty acids decreased. The total short-chain fatty acid content in the ascending colon, transverse colon, and descending colon decreased from 86.45±0.46mmol / L, 102.13±1.64mmol / L, and 89.04±5.39mmol / L to 65.77±3.46mmol / L, 75.14±1.71mmol / L, and 56.54±2.63mmol / L, respectively. After Bifidobacterium lactis YQWS2301 was added during the treatment period, all six short-chain fatty acids increased significantly, with the sum of short-chain fatty acids in the ascending colon, transverse colon, and descending colon rising to 111.01±5.11mmol / L, 96.52±1.00mmol / L, and 104.73±3.72mmol / L, respectively. This suggests that Bifidobacterium lactis YQWS2301 can increase the content of short-chain fatty acids in the intestine.
[0150] Table 8-1 Changes in short-chain fatty acid content in SHIME at different stages (mmol / L)
[0151] lactic acid Acetic acid Propionic acid Butyric acid AB <![CDATA[7.57±0.12 b ]]> <![CDATA[44.37±0.84 b ]]> <![CDATA[14.28±0.76 b ]]> <![CDATA[3.73±0.16 b ]]> AI <![CDATA[6.60±0.43 c ]]> <![CDATA[31.29±2.08 c ]]> <![CDATA[14.34±1.57 b ]]> <![CDATA[2.85±0.15 b ]]> AT <![CDATA[8.92±0.08 a ]]> <![CDATA[55.28±3.19 a ]]> <![CDATA[19.35±0.36 a ]]> <![CDATA[5.04±0.83 a ]]> TB <![CDATA[4.21±0.11 b ]]> <![CDATA[50.11±0.71 a ]]> <![CDATA[13.43±0.26 b ]]> <![CDATA[4.66±0.06 b <!-- 12 -->]]> TI <![CDATA[4.00±0.21 b ]]> <![CDATA[39.62±0.89 c ]]> <![CDATA[12.12±0.55 c ]]> <![CDATA[3.87±3.31 c ]]> TT <![CDATA[5.46±0.07 a ]]> <![CDATA[43.30±1.05 b ]]> <![CDATA[16.51±0.22 a ]]> <![CDATA[6.18±0.18 a ]]> DB <![CDATA[7.01±1.09 b ]]> <![CDATA[45.22±3.05 a ]]> <![CDATA[17.63±0.93 a ]]> <![CDATA[5.04±0.12 a ]]> DI <![CDATA[5.25±0.23 c ]]> <![CDATA[29.62±2.74 b ]]> <![CDATA[11.31±0.33 b ]]> <![CDATA[3.79±0.21 b ]]> DT <![CDATA[11.03±0.55 a ]]> <![CDATA[50.69±2.59 a ]]> <![CDATA[17.75±0.29 a ]]> <![CDATA[4.71±0.25 a ]]>
[0152] Table 8-2 Changes in short-chain fatty acid content in SHIME at different stages (mmol / L)
[0153]
[0154]
[0155] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not limiting. Although the present invention has been described with reference to the preferred embodiments of the present invention, it should be understood by those skilled in the art that various changes can be made in form and details without departing from the spirit and scope of the present invention as defined in the appended claims.
Claims
1. A Bifidobacterium lactis, characterized in that The preservation date of the Bifidobacterium lactis is January 23, 2024; the preservation unit is the General Microbiology Center of China Culture Collection Administration; the preservation address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing; the preservation number is CGMCC No.29751.
2. A Bifidobacterium lactis according to claim 1, characterized in that The gene sequence of 16S rDNA of the Bifidobacterium lactis is shown in SEQ ID NO.
1.
3. A probiotic preparation for inhibiting blood sugar increase, the probiotic preparation containing at least Bifidobacterium lactis with a preservation number of CGMCC No. 29751 and / or a supernatant component of a fermentation broth of Bifidobacterium lactis with a preservation number of CGMCC No. 29751.
4. A probiotic preparation for inhibiting blood sugar increase according to claim 3, characterized in that: The probiotic preparation contains the fermentation liquid supernatant component of Bifidobacterium lactis with a preservation number of CGMCC No.29751.
5. A probiotic preparation for inhibiting blood sugar increase according to claim 3, characterized in that: The probiotic preparation contains Bifidobacterium lactis with a preservation number of CGMCC No. 29751, and the probiotic preparation is an oral lyophilized powder preparation. The content of Bifidobacterium lactis with a preservation number of CGMCC No. 29751 in the oral lyophilized powder preparation is 1×10 9 CFU / g~150x10 9 CFU / g.
6. A probiotic preparation for inhibiting blood sugar increase according to claim 3, characterized in that: The probiotic preparation is an enteric-coated capsule or a microcapsule.
7. A probiotic preparation for inhibiting blood sugar elevation according to claim 3, characterized in that: The probiotic preparation also contains at least one of the following components: a Chinese herbal extract that assists in lowering blood sugar, Lactobacillus plantarum that assists in lowering blood sugar, Lactobacillus brevis that assists in lowering blood sugar, Lactobacillus rhamnosus that assists in lowering blood sugar, Lactobacillus casei that assists in lowering blood sugar, Lactobacillus acidophilus that assists in lowering blood sugar, Lactobacillus fermentation that assists in lowering blood sugar, Pediococcus pentosaceus that assists in lowering blood sugar, and Leuconostoc that assists in lowering blood sugar.
8. A probiotic preparation for inhibiting blood sugar elevation according to claim 7, characterized in that: The Chinese herbal extract for assisting in lowering blood sugar is selected from at least one of the following Chinese herbal extracts: Pueraria extract, Astragalus extract, Artemisia argyi flavonoids extract, Forsythia suspensa polysaccharide extract, Gardenia jasminoides flavonoids extract, Trichosanthes seed polysaccharide extract, Gynostemma pentaphyllum extract, Mulberry leaf extract, Platycodon grandiflorum extract, Lycium barbarum extract, Polygonatum sibiricum polysaccharide extract, and Achyranthes bidentata extract.
9. A method for preparing a fermentation product for inhibiting blood sugar increase, characterized in that: The fermentation product is a fermentation product of Bifidobacterium lactis with a preservation number of CGMCC No.29751, and the preparation method comprises the following steps: S1: Activate Bifidobacterium lactis with a preservation number of CGMCC No. 29751, inoculate it into TPY liquid culture medium, and culture it anaerobically at 37° C. for 48 hours to obtain a fermentation product.
10. The method for preparing a fermentation product for inhibiting blood sugar increase according to claim 9, characterized in that: The preparation method further comprises the following steps: S2: Centrifuge the fermentation product obtained in step S1 to obtain the supernatant and precipitate of the fermentation liquid.
11. The method for preparing a fermentation product for inhibiting blood sugar increase according to claim 10, characterized in that: The preparation method further comprises the following steps: S3: collecting the precipitate obtained in step S2, washing it with sterile saline, and resuspending it in reconstituted skim milk to obtain a bacterial suspension; collecting the fermentation liquid supernatant obtained in step S2, filtering it with a microporous filter membrane, and obtaining a fermentation liquid supernatant component.
12. The method for preparing a fermentation product for inhibiting blood sugar increase according to claim 11, characterized in that: The preparation method further comprises the following steps: S4: adjusting the concentration of the bacterial suspension obtained in step S3, and freeze-drying to obtain bacterial powder; and freeze-drying the supernatant component of the fermentation liquid obtained in step S3 to obtain a freeze-dried powder of the supernatant component of the fermentation liquid.
13. The method for preparing a fermentation product for inhibiting blood sugar increase according to claim 12, characterized in that: In the step S3, the mass percentage concentration of the skim milk powder in the reconstituted skim milk is 14%; further preferably, in the step S4, the concentration of the bacterial suspension before freeze-drying is adjusted to 1.0×10 10 CFU / mL~2.0×10 10 CFU / mL.
14. Use of the Bifidobacterium lactis according to claim 1 or the probiotic preparation for inhibiting blood sugar increase according to claim 3 in the preparation of a hypoglycemic agent.
15. The use according to claim 14, characterized in that: The hypoglycemic agent is an oral solid or oral liquid preparation; the hypoglycemic agent exerts a hypoglycemic effect at least by inhibiting α-amylase and α-glucosidase.
Citation Information
Cited By
Bifidobacterium animalis subsp. Lactis for relieving ulcerative colitis and constipation and application thereof
CN119331785A
